ORIGINAL ARTICLE

How frequently should asymptomatic patients be dilated?

Paul Varner

John J Pershing Veterans Affairs Medical Center, Poplar Bluff, Missouri, USA

Received 12 January 2012; accepted 8 February 2013
Available online 7 May 2013

KEYWORDS
Pupillary dilation; Frequency; Diagnostic yield

Abstract

Purpose: To determine if routine dilated fundus examination (DFE) should be performed sooner than at 10-year intervals in asymptomatic patients.

Methods: Records for all patients consecutively evaluated in a one-year time frame were systematically reviewed. Of those patients who received initial DFE and were living 10 years later, records for sequential DFE were again evaluated to determine presence of clinically-significant, peripheral retinal findings. Databases were also searched in order to determine the number of patients during the same 10-year time period who developed vision or life-threatening peripheral retinal findings. The two groups were cross-matched to determine effectiveness of routine DFE.

Results: Only 10 of 592 patients were deemed to have ‘‘clinically-significant’’ peripheral retinal findings—none of whom developed untoward outcomes. Of the 29 new retinal detachments and four intraocular tumors discovered during ten years of clinical follow-up, nearly 90% were symptomatic at the time of discovery. Three detachments and one tumor were detected as incidental findings in asymptomatic patients. No further treatment was recommended for the three detachments and the patient with the tumor survives, although with profound loss of vision in the involved eye.

Conclusions: In the absence of symptoms, routine DFE seems to have a very low yield for discovery of serious ocular events and appears to be ineffective in altering the course of incidental findings. Routine DFE is not indicated for older, asymptomatic patients—even at decade intervals. The findings of this study should be prospectively confirmed in population-based studies.

© 2012 Spanish General Council of Optometry. Published by Elsevier España, S.L. All rights reserved.

PALABRAS CLAVE
Dilatación pupilar; Frecuencia; Rendimiento diagnóstico

¿Con qué frecuencia debe dilatarse a los pacientes asintomáticos?

Resumen

Objetivo: Determinar si el examen rutinario del fondo de ojo debe realizarse con más frecuencia que a intervalos de 10 años en pacientes asintomáticos.

E-mail address: paul.varner@va.gov

1888-4296/$ - see front matter © 2012 Spanish General Council of Optometry. Published by Elsevier España, S.L. All rights reserved.
http://dx.doi.org/10.1016/j.optom.2013.03.001
**Métodos:** Se revisaron sistemáticamente las historias de todos los pacientes consecutivamente evaluados durante un período de un año. Se volvieron a evaluar las historias de aquellos pacientes cuyo fondo habría sido inicialmente examinado, y que seguían con vida 10 años después, para determinar la presencia de hallazgos con significación clínica relativa a la retina periférica. Se realizó también una búsqueda en los bases de datos para determinar el número de pacientes, durante el mismo periodo de 10 años, que había desarrollado casos en la retina periférica, con riesgo de vida o visión. Se cruzaron los dos grupos para determinar la efectividad del examen rutinario del fondo de ojo.

**Resultados:** Únicamente 10 de entre 592 pacientes mostraron casos en la retina periférica "clínicamente significativos", de los que ninguno evolucionó inadecuadamente. De los 29 nuevos desprendimientos de retina y cuatro tumores intraoculares descubiertos durante los diez años de seguimiento clínico casi el 90% fueron asintomáticos en el momento de su descubrimiento. Se detectaron tres desprendimientos y un tumor como casos incidentales en pacientes asintomáticos. No se recomendó ningún tratamiento adicional para los tres desprendimientos, y el paciente con el tumor sigue vivo, aunque con una profunda pérdida de visión en el ojo afectado.

**Conclusión:** En ausencia de síntomas, el rendimiento del examen rutinario del fondo de ojo es muy bajo a la hora de descubrir eventos oculares serios, revelándose poco eficaz para alterar el curso de los hallazgos incidentales. Dicho examen no está indicado en pacientes de edad y asintomáticos, incluso a intervalos de 10 años. Los hallazgos de este estudio deberán confirmarse prospectivamente mediante estudios basados en población.

©️ 2012 Spanish General Council of Optometry. Publicado por Elsevier España, S.L. Todos los derechos reservados.
How frequently should asymptomatic patients be dilated?

Methods

A single facility's electronic medical records database was searched for all patients consecutively evaluated in the eye clinic during a one-calendar-year period of time. Each of the records was systematically reviewed to form this retrospective, consecutive, non-comparative case series. All the medical records in this facility are electronically recorded, stored and readily available for review, thus precluding lost paper charts or record omissions.

Initial record review determined which patients received DFE during 1998. At that time, clinical protocol for this facility included DFE for most patients regardless of symptomatology. Exceptions included problem-oriented follow-up appointments for anterior segment diseases, glaucoma, refractive cases, and some neurological findings (e.g. diplopia). Those not receiving DFE were excluded from this review. A handful of patients who received multiple DFE during that year (for sequential diabetic retinopathy or AMD follow-up) were counted only once. All the 1998 patients surviving in 2008 were then identified to form the study cohort. Records were further reviewed in order to determine which of the 10-year survivors had already received DFE in 2008 or later. No specific risk factors were pre-selected for the initial cohort—the intent was to determine if there would have been any inherent clinical omissions made for patients not receiving sequential, routine DFE after ten years had passed.

Finally, attempts were made to communicate with all the remaining unaccounted-for survivors in order to repeat DFE after the decade interval. Those who declined or were unavailable for repeat examination (largely due to invalid contact information) were excluded from review. For patients from this group who may have had DFE prior to the conclusion of the 10-year interval, most recent DFE results were not carried forward.

For the patients with initial and final records at least ten years apart, peripheral retinal findings were classified as "unremarkable" (i.e. no peripheral findings, whatsoever), "remarkable" (for any peripheral findings), or "unable to grade" if visualization of retina was not possible. "Remarkable" peripheral findings were further divided into "clinically significant" or "clinically insignificant" groups.

"Clinically significant" findings represented the vast majority of patients and included lesions involving either primarily the retinal pigmented epithelium (RPE) or the neurosensory retina. RPE-level findings included window defects, hypertrophic changes, atrophic findings, choriotirenal scars, retinal pavingstone degeneration, etc. Those with predominantly neurosensory retinal findings included retinal lattice/snailtrack degeneration, white without pressure, retinoidalysis, peripheral drusen, retinoschisis, opaculated retinal tears, etc.

Those peripheral findings of potential clinical significance and deemed "remarkable" included peripheral choroidal nevi and those patients who were status post scleral buckling procedures. For both of these cases retinal findings were judged to be too anterior in location to be observable through non-mydriatic pupils. Complete stratification of patients is provided in Fig. 1.

Final observations included whether any of the patients with "remarkable" peripheral retinal findings developed any untoward peripheral retinal outcomes during the follow-up period.

Ophthalmic ICD-9 codes were searched to reveal all facility patients who developed retinal detachment (361 series) or posterior segment melanoma (190 series) during the same ten-year follow-up period (1998–2008). Each of these records was reviewed in order to determine patient symptomatology at the time of initial diagnosis and cross-referenced to the original cohort in order to determine if sequential DFE was useful in identifying these patients.

Results

A total of 2184 patients were examined during the 1998 calendar year. Of those patients, 1603 (73% of original cohort) received DFE. 874 of those patients (55% of DFE patients) were surviving and eligible for sequential DFE after a ten-year interval. Of the 874 subjects available for potential review, retinal findings for 592 patients (68% of surviving DFE patients), were available for final evaluation. The remaining 282 patients either declined repeat examination or did not have valid contact information and were unreachable by telephone or standard mail.

For the 592 patients with initial and final records ten years apart, peripheral retinal findings were classified as "unremarkable" for 69% (411/592) of the study cohort and

![Figure 1 Stratification of study patients.](image-url)
“remarkable” for 30% (176/592) of patients. The remaining 5 patients (∼1%, 5/592) were “ungradable” at decade’s end. Focus was then placed on the 176 patients deemed to have “remarkable” peripheral retinal findings.

“Clinically insignificant” retinal findings were documented for most of the “remarkable” group (166/176 or 94% of this set) after 10 years of follow-up. The remaining 10 patients (10/592, or <2% of original cohort) were deemed to be “clinically significant.” These cases were found to have peripheral choroidal nevi (n = 6) or were status post RD repairs (n = 4), although in each of these cases the patient was asymptomatic at time of DFE. Only one of the six patients with choroidal nevi demonstrated a large peripheral nevus (>10 mm in basal diameter), and this lesion had no demonstrable morphological change during the follow-up period. It should be noted that none of these ten patients developed consequential ophthalmic events, and that they all remained asymptomatic of peripheral retinal findings throughout the follow-up period.

Five patients were classified as “ungradable” due to profound ocular findings in at least one eye that precluded bilateral 10-year sequential DFE (2 mature cataracts, corneal leukemia, 2 phthisis bulbi). For each of these patients it should be noted that fellow eye DFE was unremarkable and B-scan ultrasonography did not suggest any remarkable posterior segment findings. These five patients were not included in final calculations.

For the same 10-year time-frame, 29 new retinal detachments were diagnosed. 26 of these were symptomatic, including central or peripheral visual symptoms with floaters and/or photopsia. The three new-onset, asymptomatic RDs were all delimited in nature, and all occurred as incidental findings in eyes without functional vision (previous RD, CRVO, advanced AMD). None of these three cases were ultimately treated after retinal consultation.

There were four new intraocular tumors identified during the period of regard: three melanomas and one metastatic uveal tumor. Of these, three were symptomatic (primarily with peripheral visual field changes), and one was entirely an incidental finding. This eye—diagnosed with choroidal melanoma—ultimately developed Light Perception vision despite immediate brachytherapy. The patient survived after five years of follow-up.

Conclusions

Intuitively, the inherent risk of “missing” clinically significant peripheral retinopathy must be low when considering the history of optometry prior to the widespread use of diagnostic pharmaceutical agents. Millions of undilated eye examinations were performed by optometrists, yet peripheral retinal pathologies of clinical import did not reach epidemic proportions. This review seems to provide a clinical basis for this observation.

These results are limited by the same challenges that face all retrospective studies (i.e. accuracy of medical records, difficulties in controlling for confounders/bias, hypothesis generating only); however, it is the best way to evaluate conditions of rare occurrence. The high rate of attrition from the original group of patients in terms of survival rate (only 55% of original DFE cohort was living ten years after initial DFE), is highly related to the study population (the average age of patients in this facility is 70 years of age [internal data], and predominantly male) and suggests that DFE near the end of life may be even less clinically consequential. Nearly one-third of the eligible cohort (32% of 874) was not re-examined, thus introducing real possibilities of selection bias. Another potential source of selection bias could be from the choice of the initial cohort. Inclusion of all the patients examined during a single, calendar year was chosen in order to eliminate possible bias from exclusion criteria noted in earlier studies of DFE. These shortcomings are acknowledged and it is recognized that these results may or may not be generalizable to a population including all ages of patients.

However, these results must be understood within the context of the very low risks associated with various peripheral ophthalmic conditions11-15 and the low yield of “clinically significant” peripheral retinal findings on initial routine DFE.16 This review’s finding that the identification of a single retinal finding of clinical importance in an asymptomatic patient out of ten years of follow-up of 592 older patients—and that the outcome of that single case was not altered by presymptomatic diagnosis—confirms earlier suggestions that the “value” of routine DFE remains low.17 This study fails to disprove that null hypothesis.

The dangling implication of this report is that it remains entirely possible that an older, asymptomatic patient may never require DFE during the course of his or her life. Long-term prospective, population-based study is required to follow up on this intriguing hypothesis and to provide medical evidence to substantiate an old clinical practice. In the final analysis, patient symptomatology continues to be the single most important factor in discovering highly significant peripheral retinal findings. To answer the question posed by the title of this article then, clinicians must recognize that it is quite possibly “never.”

Conflicts of interest

Dr. Varner reports no financial conflicts of interest.

Acknowledgements

The author would like to thank Dr. Nanette Gunn, LaDonna Johnson, Dr. Tyler Kramer, Ed Sheffield, and Gayle Veness for their assistance with data collection, and Antonia Varner for the figure design.

The views expressed in this article are those of the author and do not necessarily represent the position of the Department of Veterans Affairs.

References

How frequently should asymptomatic patients be dilated?


